Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

April 15, 2024

Study Completion Date

December 31, 2025

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Folinic Acid

Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.

OTHER

Placebo

Inactive placebo comparator

Trial Locations (4)

11203

State University of New York, Downstate, Brooklyn

30322

Children's Healtcare of Atlanta, Atlanta

85016

Southwestern Research and Resource Center, Phoenix

02421

Harvard University, Lexington

All Listed Sponsors
collaborator

Emory University

OTHER

collaborator

Harvard University

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

State University of New York - Downstate Medical Center

OTHER

lead

Southwest Autism Research & Resource Center

OTHER